
DTIL
7.72 USD
-5.80%
Today
-5.45%
1D
Market is open
Sun
Closed
Mon
4:30 PM ~ 10:59 PM
Tue
4:30 PM ~ 10:59 PM
Wed
4:30 PM ~ 10:59 PM
Thu
4:30 PM ~ 10:59 PM
Fri
4:30 PM ~ 10:59 PM
Sat
Closed
Information
Name
Precision BioSciences
Currency
USD
Market Cap
277.50M
Avg Daily Volume
3.00
52 Week High
10 USD
52 Week Low
2.88 USD
Trading Hours
See hours
Business Summary
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing therapies for gene edits, including gene insertion, excision, and elimination in the United States. The company offers ARCUS, a genome editing platform for DNA genome insertion, removal, and repair. It also provides PBGENE-HBV for the treatment of chronic hepatitis B virus (HBV) to eliminate covalently closed circular DNA with direct cuts and edits, as well as to inactivate integrated HBV DNA with the goal of long-lasting reductions in hepatitis B surface antigen; and PBGENE-DMD (Excision) for the treatment of Duchenne muscular dystrophy. In addition, the company develops PBGENE-3243 for the treatment of m.3243 associated mitochondrial diseases; and iECURE-OTC (Insertion) for ornithine transcarbamylase deficiency. It has collaboration agreements with TG Cell Therapy, Inc. to develop, manufacture, and commercialize azercabtagene zapreleucel for autoimmune diseases and other indications; and iECURE, Inc., an ARCUS-mediated targeted gene insertion. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Top News
Precision.Bio
-4.01%
DTIL: HBV phase II and DMD biopsy catalysts set up a data-rich 2027
tradingview.com
3d ago

Precision.Bio
-4.01%
DTIL: Phase I HBV data support 0.4 mg/kg and a global phase II cure test
tradingview.com
4d ago

Precision.Bio
-4.01%
DTIL: 0.4 mg/kg data support Phase 2 testing of cccDNA elimination as a potential HBV cure
tradingview.com
4d ago

Show more
Frequently Asked Questions
What are healthcare stocks and why are they important to investors?
Healthcare stocks include pharmaceutical companies, biotech firms, hospitals, and medical device manufacturers.
Are healthcare stocks less volatile?
Generally yes. Because healthcare is a necessity, demand remains relatively steady, making the sector less sensitive to economic cycles.
What drives growth in healthcare investments?
Aging populations, technological advancements, and increased healthcare spending contribute to long-term growth in the sector.
What are the risks of investing in healthcare?
Regulatory changes, drug approval delays, and legal challenges can affect the profitability and stock prices of healthcare companies.

